Focus: Lexeo Therapeutics is a New York-based gene therapy biotech focused on treating rare neurological and cardiac diseases. The company operates at early clinical stages with a lean pipeline of Phase 1/2 programs.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Stable — net +4 jobs in 30d
7 added, 3 removed. Backfill posture.
Best suited for early-career scientists or specialists seeking hands-on gene therapy expertise in rare disease; career risk depends on undisclosed cash runway and post-acquisition integration success.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lexeo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lexeo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout - TradingView
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout TradingView
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow (NASDAQ:LXEO) 2026-10-24 - Seeking Alpha
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow (NASDAQ:LXEO) 2026-10-24 Seeking Alpha
Lexeo Therapeutics, Inc. Estimates – NASDAQ:LXEO - TradingView
Lexeo Therapeutics, Inc. Estimates – NASDAQ:LXEO TradingView
Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History Yahoo! Finance Canada
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM - GlobeNewswire
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM GlobeNewswire
JPMorgan reports ownership above 5% in Lexeo Therapeutics (LXEO). - Stock Titan
JPMorgan reports ownership above 5% in Lexeo Therapeutics (LXEO). Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo